• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

BMS, Pfizer and Merck face steep patent cliffs but all have the financial flexibility for...

cafead

Administrator
Staff member
  • cafead   Jun 22, 2022 at 12:02: AM
via Bristol Myers Squibb, Pfizer and Merck will face extreme patent cliff exposure later in this decade. But those companies also have the financial flexibility to perform mergers and acquisitions to overcome the anticipated losses.

article source
 

<